PharmaShots | Incisive News in 3 Shots

Subscribe Now

Terminate Two

Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer's Disease

Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer's Disease

September 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us